|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Cin. 62:10–29. 2012. View Article : Google Scholar
|
|
2
|
Hrašovec S and Glavač D: MicroRNAs as
novel biomarkers in colorectal cancer. Front Genet. 3:1802012.
|
|
3
|
Cunningham JM, Christensen ER, Tester DJ,
et al: Hypermethylation of the hMLH1 promoter in colon
cancer with microsatellite instability. Cancer Res. 58:3455–3460.
1998.PubMed/NCBI
|
|
4
|
Toyota M, Ahuja N, Ohe-Toyota M, Herman
JG, Baylin SB and Issa JP: CpG island methylator phenotype in
colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shen L, Toyota M, Kondo Y, et al:
Integrated genetic and epigenetic analysis identifies three
different subclasses of colon cancer. Proc Natl Acad Sci USA.
104:18654–18659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fazi F and Nervi C: MicroRNA: basic
mechanisms and transcriptional regulatory networks for cell fate
determination. Cardiovasc Res. 79:553–561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meister G and Tuschl T: Mechanisms of gene
silencing by double-stranded RNA. Nature. 431:343–349. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: how many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lim LP, Lau NC, Garrett-Engele P, et al:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Corney DC, Flesken-Nikitin A, Godwin AK,
Wang W and Nikitin AY: MicroRNA-34b and MicroRNA-34c
are targets of p53 and cooperate in control of cell proliferation
and adhesion-independent growth. Cancer Res. 67:8433–8438. 2007.
View Article : Google Scholar
|
|
12
|
He L, He X, Lim LP, et al: A microRNA
component of the p53 tumour suppressor network. Nature.
447:1130–1134. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tarasov V, Jung P, Verdoodt B, et al:
Differential regulation of microRNAs by p53 revealed by massively
parallel sequencing: miR-34a is a p53 target that induces apoptosis
and G1-arrest. Cell Cycle. 6:1586–1593. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang TC, Wentzel EA, Kent OA, et al:
Transactivation of miR-34a by p53 broadly influences gene
expression and promotes apoptosis. Mol Cell. 26:745–752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bommer GT, Gerin I, Feng Y, et al:
p53-mediated activation of miRNA34 candidate tumor-suppressor
genes. Curr Biol. 17:1298–1307. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Toyota M, Suzuki H, Sasaki Y, Maruyama R,
Imai K, Shinomura Y and Tokino T: Epigenetic silencing of
microRNA-34b/c and B-cell translocation gene 4 is
associated with CpG island methylation in colorectal cancer. Cancer
Res. 68:4123–4132. 2008.PubMed/NCBI
|
|
18
|
Kozaki K, Imoto I, Mogi S, Omura K and
Inazawa J: Exploration of tumor-suppressive microRNAs silenced by
DNA hypermethylation in oral cancer. Cancer Res. 68:2094–2105.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lujambio A, Calin GA, Villanueva A, et al:
A microRNA DNA methylation signature for human cancer metastasis.
Proc Natl Acad Sci USA. 105:13556–13561. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kong YW, Ferland-McCollough D, Jackson TJ
and Bushell M: microRNAs in cancer management. Lancet Ooncol.
13:e249–e258. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lujambio A, Ropero S, Ballestar E, et al:
Genetic unmasking of an epigenetically silenced microRNA in human
cancer cells. Cancer Res. 67:1424–1429. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Iwai N and Naraba H: Polymorphisms in
human pre-miRNAs. Biochem Biophys Res Commun. 331:1439–1444. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Y, Liu L, Liu J, et al: A potentially
functional polymorphism in the promoter region of miR-34b/c is
associated with an increased risk for primary hepatocellular
carcinoma. Int J Cancer. 128:412–417. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gao LB, Li LJ, Pan XM, Li ZH, Liang WB,
Bai P, Zhu YH and Zhang L: A genetic variant in the promoter region
of miR-34b/c is associated with a reduced risk of colorectal
cancer. Biol Chem. 394:415–420. 2013.PubMed/NCBI
|
|
25
|
Hiroki E, Suzuki F, Akahira J, Nagase S,
Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H and Yaegashi N:
MicroRNA-34b functions as a potential tumor suppressor in
endometrial serous adenocarcinoma. Int J Cancer. 131:E395–E404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bensen JT, Tse CK, Nyante SJ,
Barnholtz-Sloan JS, Cole SR and Millikan RC: Association of
germline microRNA SNPs in pre-miRNA flanking region and breast
cancer risk and survival: the Carolina Breast Cancer Study. Cancer
Causes Control. 24:1099–1109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ahmed RL, Schmitz KH, Anderson KE,
Rosamond WD and Folsom AR: The metabolic syndrome and risk of
incident colorectal cancer. Cancer. 107:28–36. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Moghaddam AA, Woodward M and Huxley R:
Obesity and risk of colorectal cancer: a meta-analysis of 31
studies with 70,000 events. Cancer Epidemiol Biomarkers Prev.
16:2533–2547. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wittke-Thompson JK, Pluzhnikov A and Cox
NJ: Rational inferences about departures from Hardy-Weinberg
equilibrium. Am J Hum Genet. 76:967–986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chou J, Provot S and Werb Z: GATA3 in
development and cancer differentiation: cells GATA have it! J Cell
Physiol. 222:42–49. 2010.
|
|
31
|
Xiang Y, Fan S, Cao J, Huang S and Zhang
LP: Association of the microRNA-499 variants with susceptibility to
hepatocellular carcinoma in a Chinese population. Mol Biol Rep.
39:7019–7023. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin J, Horikawa Y, Tamboli P, Clague J,
Wood CG and Wu X: Genetic variations in microRNA-related genes are
associated with survival and recurrence in patients with renal cell
carcinoma. Carcinogenesis. 31:1805–1812. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu Z, Chen J, Tian T, et al: Genetic
variants of miRNA sequences and non-small cell lung cancer
survival. J Clin Invest. 118:2600–2608. 2008.PubMed/NCBI
|
|
34
|
Dumont P, Leu JI, Della Pietra AC III,
George DL and Murphy M: The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 33:357–365.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Irarrázabal CE, Rojas C, Aracena R,
Márquez C and Gil L: Chilean pilot study on the risk of lung cancer
associated with codon 72 polymorphism in the gene of protein p53.
Toxicol Lett. 144:69–76. 2003.PubMed/NCBI
|
|
36
|
Kuroda Y, Tsukino H, Nakao H, Imai H and
Katoh T: p53 codon 72 polymorphism and urothelial cancer
risk. Cancer Lett. 189:77–83. 2003. View Article : Google Scholar
|
|
37
|
Suzuki K, Matsui H, Ohtake N, et al: A p53
codon 72 polymorphism associated with prostate cancer development
and progression in Japanese. J Biomed Sci. 10:430–435. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dahabreh IJ, Linardou H, Bouzika P,
Varvarigou V and Murray S: TP53 Arg72Pro polymorphism and
colorectal cancer risk: a systematic review and meta-analysis.
Cancer Epidemiol Biomarkers Prev. 19:1840–1847. 2010. View Article : Google Scholar
|
